Welcome to LookChem.com Sign In|Join Free
  • or
Benzeneacetamide, 4-fluoro--alpha--hydroxy- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

959025-07-1

Post Buying Request

959025-07-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

959025-07-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 959025-07-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,9,0,2 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 959025-07:
(8*9)+(7*5)+(6*9)+(5*0)+(4*2)+(3*5)+(2*0)+(1*7)=191
191 % 10 = 1
So 959025-07-1 is a valid CAS Registry Number.

959025-07-1Downstream Products

959025-07-1Relevant academic research and scientific papers

Condensation of vilsmeier salts, derived from tetraalkylureas, with α-hydroxy amide derivatives: One-pot approach to synthesize 2-dialkylamino-2-oxazolin-4-ones

Liu, Bengen,Su, Dongshan,Wei, Zhonglin,Cao, Jungang,Liang, Dapeng,Lin, Yingjie,Duan, Haifeng

supporting information, p. 249 - 252 (2017/02/10)

A novel and straightforward synthetic protocol was developed to synthesize 2-dialkylamino-2-oxazolin-4-ones from various Vilsmeier salts and α-hydroxy amides derivatives. Notably, thozalinone (3a), as a mild stimulant in tristimania and anorexic, could be synthesized simply and in a high yield using this methodology.

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

-

, (2018/01/20)

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 959025-07-1